



WORLD CORD BLOOD CONGRESS III

Rome, Italy

October 27-29, 2011

President: Eliane Gluckman (Paris)

Eurocord-ED Local Organizers : W. Arcese (Rome), F. Locatelli (Rome), P. Rebulla (Milan)

EBMT Immunobiology Working Party: A. Madrigal (London),

A. Toubert (Paris), A. Velardi (Perugia),

Netcord: E. Baudoux (Liège), C. Navarrete (London)

PROGRAMME

Thursday, October 27, 2011

SESSION 1: CORD BLOOD BANKING - CHAIR : P. REBULLA

08:30-08:40: Introduction and State of the Art	P. Rebulla (Milan)
08:40-09:00: Quality of Cord Blood Banking	R. Saccardi (Florence)
09:00-09:20: Towards more rational allogeneic cord blood inventories	S. Querol (Barcelona)
09:20-09:40: Directed Cord Blood Banking	E. Gluckman (Paris)
09:40-10:00: Review of international fees for cord blood procurement	C. Navarrete (London)
10:00-10:30: Panel discussion	

10:30-11:00: Coffee break

SESSION 2: CORD BLOOD STEM CELLS - CHAIR : H. BROXMEYER

11:00-11:30: Introduction and state of the art	H. Broxmeyer (Indianapolis)
11:30-11:50: Characterization of non haematopoietic stem cells in cord blood	G. Kögler (Dusseldorf)
11:50-12:30: Panel discussion Is there a place of cord blood in Regenerative Medicine?	J. Wagner (Minneapolis) & J. Kurtzberg (Durham)

12:30-13:30 Lunch

SESSION 3-9: HOW TO IMPROVE CBT OUTCOMES - CHAIR: F. LOCATELLI

13:30-14:00: Introduction and State of the Art	F. Locatelli (Rome)
--	---------------------

SESSION 3: HOW TO IMPROVE ENGRAFTMENT - CHAIR: V. ROCHA

14:00-14:20: Single CBT: The importance of cell dose	V. Rocha (Paris)*
14:20-14:40: Double CBTs : when, how for whom ?	J. Wagner (Minneapolis)
14:40-15:00: Intrabone CBT : Still experimental or standard practice ?	F. Frassoni (Genoa)
15:00-15:20: Ex vivo expansion of CB cells: Is still a possible option	E.J Shpall (Houston)*

15:20-15:40: Coffee break

SESSION 4: HOW TO IMPROVE PREPARATIVE REGIMENS - CHAIR: J.WAGNER

15:40-16:00: In favour of myeloablative regimens	W. Arcese (Rome)
16:00-16:20: In favour of reduced intensity regimens	A. Ruggeri (Milan)
16:20-18:00 Panel discussion on the best regimens to improve outcomes	TBA

Welcome reception

Friday, October 28, 2011

SESSION 5-7: HOW TO IMPROVE IMMUNE RECONSTITUTION (JOINT SESSION WITH EBMT-IWP)

SESSION 5: SELECTING “ GOOD PROGNOSIS” DONORS - CHAIR: A. VELARDI

08:30-08:50: Introduction and State of the Art: KIR and KIR-ligands	A. Velardi (Perugia)
08:50-09:10: New methods of selecting donors	E. Petersdorf (Seattle)*
09:10-09:20: Role of High resolution HLA typing	R. Cunha (Paris)
09:20-09:40: Role of NIMA	JJ Van Rood (Leiden) *
09:40-10:00: Selection of double cord blood units	J. Wagner (Minneapolis)
10:00-10:30: Panel discussion Algorithm of donor search	V. Rocha (Paris)*

10:30-10:50: Coffee break

SESSION 6: BOOSTING IMMUNE RECONSTITUTION - CHAIR: A. TOUBERT

10:50-11:20: Introduction and state of the art	A. Toubert (Paris)
11:20-11:40: Immune reconstitution in CBT: critical issues	A. Madrigal (London)
11:40-12:00: Expanding lymphoid progenitors to improve post-transplant immune reconstitution	M. Van den Brink (New York)
12:00-12:20: From NK to thymus: innovative ways to rebuild immune response	A. Velardi (Perugia)
12:20-12:40: Invariant NKT cells: a new key player in cord blood and haploidentical stem cell transplantation	P. Dellabona (Milan)

12:40-13:00: **Discussion**

13:00 - 14:00 : Lunch

SESSION 7: ADOPTIVE CELLULAR IMMUNOTHERAPIES - CHAIR: A. MADRIGAL

14:00-14:20: Multivirus specific CTLs obtained from CB : a revolution in preventing life-threatening infections?	C. Bollard (Houston)*
14:20-14:40: Third-party CTLs for treatment of viral infections after CBT	B. Savoldo (Houston)*
14:40-15:00: MSCs for GVHD prevention/treatment	W. Fibbe (Leiden)
15:00-15:20: Regulatory T Cells in CBT	J. Wagner (Minneapolis)
15:20-15:40: Anti-leukemia CB CTLs	E.J Shpall (Houston)*

15:40-16:10 : Coffee break

16:10-17:10: Selected abstracts oral presentations
17:10-18:00: Panel discussion on adoptive immunotherapy

SESSION 8: COMPARISON WITH OTHER STEM CELL SOURCES : PRO AND CONS - CHAIR : M. HOROWITZ

08:30-09:00: Intoduction and state of the art	M. Horowitz (Milwaukee)*
09:00-09:20: Cord blood results - What are the advantages ?	V. Rocha (Paris)*
09:20-09:50: Haploidentical results - T deplete or not ?	W. Arcese (Rome)
09:50-10:10: Matched unrelated bone marrow or peripheral blood stem cells; comparison with other sources	M. Eapen (Milwaukee)
10:10-10:40: Specific paediatric aspects	J. Kurtzberg (Duhram)

10:40-11:00 : *Coffee break*

SESSION 9: LATE COMPLICATION

11:00-11:20: Donor cell malignancies	S. Querol (Barcelona)
11:20-11:40: Chronic GVH: is it really less severe ?	A. Crotta (Milan)
11:40-12:00: Autoimmune disease : is it more frequent after CBT than after adults BMT or PBSC ?	D. Farge (Paris)
12:00-13:00: Panel discussion	

End of the meeting

*** *Pending confirmation***